Cystinosis is a rare inherited lysosomal storage disorder caused by mutations in the CTNS gene, leading to toxic accumulation of cystine inside cells. This results in progressive, multi-organ damage, especially affecting the kidneys. Current standard therapy with cysteamine only slows disease progression and requires lifelong adherence.
**Hematopoietic stem-cell gene therapy**offers a disease-modifying approach by correcting the genetic defect itself. In this strategy, a patient’s own blood-forming stem cells are collected and genetically engineered to carry a functional CTNS gene. After reinfusion, these corrected cells engraft in the bone marrow and continuously produce cystinosin, the missing lysosomal transporter.
The gene-corrected cells migrate to various tissues, helping reduce intracellular cystine levels and potentially preventing further organ damage. Early clinical results demonstrate acceptable safety and sustained biological activity, suggesting this could become a one-time, long-term therapeutic option for cystinosis rather than lifelong symptomatic treatment.
Impact:
This approach represents a major step toward curative therapy for rare genetic metabolic disorders.
